Apogee Therapeutics Inc. emerged from stealth with $169 million in financing and a pipeline of four preclinical antibody development programs that take aim at major immunological and inflammatory disorders.
The age-old separation of dentistry from medicine is deeply embedded in education and professional practice. Given the great advances in both disciplines in recent decades, there is a reasonable argument to be made for maintaining the divide.
Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The transposition of DNA elements triggers an inflammatory response involved in the survival of cancer cells, a mechanism that could be blocked applying reverse transcriptase inhibitors, a class of drugs better known as anti-HIV medications.
Researchers from Eydis Bio Inc. reported the discovery and preclinical characterization of a novel mitogen-activated protein kinase kinase kinase 7 (MAP3K7/TAK1) inhibitor, EYD-001, being developed for the treatment of inflammatory and neuropathic pain.
C4X Discovery Holdings plc has outlicensed its once daily oral NRF2 (Nuclear factor-erythroid factor 2-related factor 2) activator to Astrazeneca plc in a deal with a potential value of $402 million. Of that, $2 million is being paid up front, with a further $14 million in preclinical milestones, which C4X CEO Clive Dix expects to trigger within the next two years.
Silo Pharma Inc. plans to initiate a pilot study of SPU-21, its novel joint-homing peptide targeting rheumatoid arthritis (RA), in human synovial tissue surrounding joints and tendons.
A research team at Duality Biologics (Suzhou) Co. Ltd. has discovered a novel anti-TNF-α monoclonal antibody-drug conjugate (ADC), DB-2306, as a potential therapeutic candidate for the treatment of autoimmune disease.
Sitryx Therapeutics Ltd. has disclosed 2-methylene-4-oxo-butanoic acid derivative compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.
An in-depth investigation of the underlying causes of pulmonary symptoms that in some cases persist for months following recovery from the acute stage of COVID-19 has found a distinctive proinflammatory signature in the plasma and airways of affected patients.
An in-depth investigation of the underlying causes of pulmonary symptoms that in some cases persist for months following recovery from the acute stage of COVID-19 has found a distinctive proinflammatory signature in the plasma and airways of affected patients. The research could provide an explanation for the ongoing interstitial lung disease and fibrosis seen in patients who were hospitalized with severe COVID-19, and also point to neutrophils as a specific therapeutic target.
RSS
